Cupid lifts FY27 guidance as consumer-products expansion accelerates

Cupid has raised its FY27 revenue guidance to ₹725–750 crore and net-profit outlook to ₹210–225 crore, citing consumer-product distribution, FMCG launches, capacity expansion and healthcare orders. Its consumer business contributed about ₹122 crore in FY26.

By ·Devil's-advocate pass

Source published First seen Source Mint · Markets

The development

Cupid raised FY27 revenue and profit guidance following strong quarterly growth, supported by Bharat consumer-product distribution, new FMCG launches, manufacturing expansion and global healthcare orders. Its consumer business generated about ₹122 crore in FY26, with new capacity due next quarter.

The numbers

  • FY27 revenue guidance: ₹725–750 crore
  • FY27 net profit guidance: ₹210–225 crore
  • Q1 FY27 total income: ₹157 crore, up 142% YoY
  • Q1 FY27 PAT: ₹44 crore, up 194% YoY
  • Q1 FY27 EBITDA margin: 39%
  • FY28 revenue target: ₹1,085 crore
  • FY29 revenue target: ₹1,500 crore
  • FY26 consumer-business contribution: approximately ₹122 crore
  • Palava facility capacity: 1.25 billion male condoms and 125 million female condoms annually

Why it matters to operators and investors

Cupid’s accelerating consumer business, which contributed about ₹122 crore in FY26, makes it a more relevant partner or target in sexual wellness, FMCG distribution and healthcare-product adjacencies.

What to watch next

  • Quarterly consumer-products revenue growth versus the FY26 base of roughly ₹122 crore.
  • Consumer-business gross margin and advertising, promotion and trade-spend intensity.
  • New distribution points, pharmacy coverage, e-commerce ranking and repeat-order metrics.
  • Capacity commissioning dates, utilization rates and working-capital movement.
  • Healthcare-order wins, delivery schedules and receivable collections.
  • Any change in FY27 revenue guidance of ₹725–750 crore or net-profit guidance of ₹210–225 crore.
  • Accelerate general-trade, pharmacy, e-commerce and modern-trade distribution for consumer brands.
  • Prioritize high-repeat, higher-margin sexual-wellness and personal-care SKUs over low-velocity launch breadth.
  • Use capacity expansion to improve in-house production economics while avoiding excess finished-goods inventory.
  • Convert healthcare and institutional order pipeline into scheduled deliveries to reduce quarterly revenue volatility.
  • Increase brand investment selectively and track customer-acquisition cost, repeat purchase and distributor reorder rates.